| 1 | 2407039-29-4 | Tofacitinib Impurity 45 | Tofacitinib Impurity 45 | C16H20N6O2
| 杂质对照品;有机中间体 | |
| 2 | 1640971-51-2 | 托法替尼代谢物-1 | Tofacitinib metabolite-1 | C16H20N6O2
| 托法替尼 | |
| 3 | 361481-40-5 | ethyl ethyl-4-(4-toluidino)quinoline-3-carboxylate | ethyl ethyl-4-(4-toluidino)quinoline-3-carboxylate | C16H20N6O2
| | |
| 4 | | 4,4'-[1,2-Ethanediylbis(oxy)]bis[3-aminobenzamidine] | 4,4'-[1,2-Ethanediylbis(oxy)]bis[3-aminobenzamidine] | C16H20N6O2
| | |
| 5 | 1164099-00-6 | 4,4'-bis[(2-aminoethyl)aminocarbonyl]-2,2'-bipyridine | 4,4'-bis[(2-aminoethyl)aminocarbonyl]-2,2'-bipyridine | C16H20N6O2
| | |
| 6 | | 2,4-Diamino-6-ethyl-5-(3-nitro-4-(pyrrolidin-1-yl)phenyl)pyrimidine | 2,4-Diamino-6-ethyl-5-(3-nitro-4-(pyrrolidin-1-yl)phenyl)pyrimidine | C16H20N6O2
| | |
| 7 | | 1-(2-Dimethylaminoethyl)-2-(5-nitro-1-ethyl-1H-imidazol-2-yl)-1H-benzimidazole | 1-(2-Dimethylaminoethyl)-2-(5-nitro-1-ethyl-1H-imidazol-2-yl)-1H-benzimidazole | C16H20N6O2
| | |
| 8 | 956371-02-1 | 4-[4-(3,4-DIMETHOXYBENZYL)-5-METHYL-4H-1,2,4-TRIAZOL-3-YL]-1-METHYL-1H-PYRAZOL-5-AMINE | 4-[4-(3,4-DIMETHOXYBENZYL)-5-METHYL-4H-1,2,4-TRIAZOL-3-YL]-1-METHYL-1H-PYRAZOL-5-AMINE | C16H20N6O2
| | |
| 9 | 866040-05-3 | ETHYL 4-([3-(1H-IMIDAZOL-1-YL)PROPYL]AMINO)-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE | ETHYL 4-([3-(1H-IMIDAZOL-1-YL)PROPYL]AMINO)-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE | C16H20N6O2
| | |
| 10 | 2028267-73-2 | 托法替尼杂质24 | N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide | C16H20N6O2
| 托法替尼;杂质对照品;托法替尼杂质;076-托法替尼 | 杂质对照品;托法替尼杂质;托法替尼;076-托法替尼 |
| 11 | 1269823-96-2 | 托法替布杂质 | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-6-oxo-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo- | C16H20N6O2
| | |